Literature DB >> 3690224

Prognostic significance of oestrogen and progestogen receptor activities in breast cancer.

R A Hawkins1, G White, N J Bundred, J M Dixon, W R Miller, H J Stewart, A P Forrest.   

Abstract

The prognostic significance of the tumour activities of 2 steroid receptors, those for oestrogen (ER) and for progestogen (PgR), has been studied in 372 patients with breast cancer, in whom follow-up was available for 2-6 years (median 41 months). Of 252 patients with operable disease, 75.8 per cent had ER-positive tumours and 46.4 per cent had PgR-positive tumours, though a small additional fraction (6.3 per cent) had an equivocal PgR assay result. For the 236 patients with unequivocal receptor status, the relationships between disease-free interval or overall survival and receptor activity and other factors were evaluated by univariate and multivariate analyses. The latter revealed that only tumour size, node status, menstrual status and ER status related significantly to both disease-free interval and survival, though adjuvant therapy also related to disease-free interval, and tumour grade related to survival. It is concluded that measurements of PgR activity do not add to the prognostic significance of ER status.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3690224     DOI: 10.1002/bjs.1800741118

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  11 in total

1.  Progesterone Receptor (PGR) Gene Variants Associated with Breast Cancer and Associated Features: a Case-Control Study.

Authors:  Rabeb M Ghali; Maryam A Al-Mutawa; Bashayer H Ebrahim; Hanen H Jrah; Sonia Zaied; Hanen Bhiri; Fahmi Hmila; Touhami Mahjoub; Wassim Y Almawi
Journal:  Pathol Oncol Res       Date:  2018-01-04       Impact factor: 3.201

2.  Epidermal growth factor receptors in intracranial and breast tumours: their clinical significance.

Authors:  R A Hawkins; E Killen; I R Whittle; W J Jack; U Chetty; R J Prescott
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

3.  Expression of glutathione S-transferase B1, B2, Mu and Pi in breast cancers and their relationship to oestrogen receptor status.

Authors:  A F Howie; W R Miller; R A Hawkins; A R Hutchinson; G J Beckett
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640

4.  Is apocrine differentiation in breast carcinoma of prognostic significance?

Authors:  N J Bundred; R A Walker; D Everington; G K White; H J Stewart; W R Miller
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

5.  Prospective evaluation of prognostic factors in operable breast cancer.

Authors:  R A Hawkins; A L Tesdale; M E Killen; W J Jack; U Chetty; J M Dixon; M J Hulme; R J Prescott; M A McIntyre; W R Miller
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

Review 6.  Oestrogen receptor: a stable phenotype in breast cancer.

Authors:  J F Robertson
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

7.  Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.

Authors:  E D Anderson; A P Forrest; P A Levack; U Chetty; R A Hawkins
Journal:  Br J Cancer       Date:  1989-08       Impact factor: 7.640

8.  Measurement of oestrogen receptor mRNA levels in human breast tumours.

Authors:  J A Henry; S Nicholson; J R Farndon; B R Westley; F E May
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

9.  pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response.

Authors:  J A Henry; N H Piggott; U K Mallick; S Nicholson; J R Farndon; B R Westley; F E May
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

10.  Outcome after extended follow-up in a prospective study of operable breast cancer: key factors and a prognostic index.

Authors:  R A Hawkins; A L Tesdale; R J Prescott; T Forster; M A McIntyre; P Baker; W J L Jack; U Chetty; J M Dixon; M E Killen; M J Hulme; W R Miller
Journal:  Br J Cancer       Date:  2002-07-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.